Navigation Links
Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
Date:6/2/2011

SAN DIEGO, June 2, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the Jefferies 2011 Global Healthcare Conference in New York. The presentation is scheduled for June 9 at 11:00 a.m. EDT (8:00 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter and ViroPharma to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin and Cinryze®. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Halozyme Contact  
Robert H. Uhl
Senior Director, Investor Relations
(858) 704-8264
ruhl@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
2. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
3. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
4. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
5. Halozyme Receives $5.5 Million Payment From Baxter
6. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
7. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
8. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
9. Halozyme Therapeutics to Present at Upcoming Investor Conferences
10. Halozyme Therapeutics to Host Research Day for Investors and Analysts
11. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... SAN FRANCISCO , February 12, 2016 /PRNewswire/ ... Precision Medicine Efforts by Enabling Scientific Understanding of ... Disorders and Rare Diseases --> ... for genomic diagnostics in South Asia and a leading ... it would contribute $10 million to the GenomeAsia ...
(Date:2/11/2016)... , Germany and ... QGEN ; Frankfurt Prime Standard: QIA) today ... Targeted RNA Panels for gene expression profiling, expanding QIAGEN,s ... (NGS). The panels enable researchers to select from over ... changes and discover interactions between genes, cellular phenotypes and ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... to delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals ... a premier sponsor of the 2016 BioProcess International Awards – Recognizing Excellence ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... more than 150 years, continues today to pursue the highest level of accuracy ... analytical instruments: the AR9 Refractometer and the AR5 Refractometer. Accurate, reliable and ...
Breaking Biology Technology:
(Date:2/9/2016)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics software ... year ended December 31, 2015.  --> ... $6.9 million, an increase of 61% compared to $4.3 million in ... of 2015 was $2.6 million compared to $0.2 million in the ... --> Higher revenue and operating income in the fourth quarter ...
(Date:2/4/2016)... , Feb. 4, 2016 The field ... one of the most popular hubs of the ... and other huge studies of human microbiota, have ... few years, the microbiome space has literally exploded ... research. This report focuses on biomedical aspects ...
(Date:2/3/2016)... , Feb. 3, 2016 ... addition of the "Emotion Detection and ... Learning, and Others), Software Tools (Facial Expression, ... End Users,and Regions - Global forecast to ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced ...
Breaking Biology News(10 mins):